LGVN — Longeveron Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1721484 ·
Last close
$0.84
Market Cap
$25.50M
52W High
$0.89
52W Low
$0.57
ADV30
435,367
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 398,000 | 264,000 | -4,775,000 | -4,736,000 | 21,210,000 | 15,758,000 | 5,183,000 |
| Dec 2025 | 365,000 | 257,000 | -5,399,000 | -5,444,000 | 10,261,000 | 4,661,000 | 4,586,000 |
| Sep 2025 | 137,000 | 125,000 | -7,310,000 | -7,221,000 | 15,557,000 | 9,244,000 | 5,591,000 |
| Jun 2025 | 316,000 | 146,000 | -5,397,000 | -5,028,000 | 16,749,000 | 10,334,000 | 4,093,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,318,000
Investing CF
$-465,000
Financing CF
$20,214,000
CapEx
$-465,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.25
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-137,047,000
Inventory
—
Receivables
$68,000
ST Investments
$0
EBIT TTM
$-22,881,000
Pretax Income TTM
$-22,429,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,187,000
EBITDA
$-22,440,000
Free Cash Flow
$-11,603,375
Enterprise Value
$17,441,084
Total Cash
$10,077,000
Total Debt
$581,000
Shares Out
30,432,974
Trailing EPS
$-1.00
Book Value
$0.33
ROE
-203.6%
ROA
-90.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,199,000 | -23,287,000 | -22,704,000 | 10,261,000 | 4,586,000 | — | -18,645,000 |
| Dec 2024 | 2,392,000 | -16,522,000 | -15,973,000 | 25,558,000 | 3,671,000 | — | -13,868,000 |
| Dec 2023 | 709,000 | -21,029,000 | -21,413,000 | 12,078,000 | 5,337,000 | — | -19,002,000 |
| Dec 2022 | 1,222,000 | -18,043,000 | -18,835,000 | 27,413,000 | 6,910,000 | — | -13,969,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.53
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ETST | Earth Science Tech, Inc. | $25.88M | $0.09 | — |
| MRKR | Marker Therapeutics, Inc. | $25.01M | $1.50 | — |
| AYTU | AYTU BIOPHARMA, INC | $24.79M | $2.31 | — |
| ATOS | ATOSSA THERAPEUTICS, INC. | $26.35M | $2.64 | — |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | $24.67M | $0.06 | — |
News headlines (Yahoo Finance, 1h cache)
Longeveron Announces 1-for-10 Reverse Stock Split
2026-08-24 20:05 · Yahoo
Longeveron (LGVN) Q2 2026 Earnings Call Transcript
2026-08-19 21:58 · Yahoo
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
2026-08-19 20:05 · Yahoo
LGVN at a Major Inflection Point
2026-08-13 12:07 · Yahoo
Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
2026-08-03 20:05 · Yahoo
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
2026-07-23 13:15 · Yahoo
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Pat
2026-07-13 11:05 · Yahoo
Longeveron to Present at BIO International Convention 2026
2026-06-04 13:15 · Yahoo
LGVN Set for Success in 2026
2026-05-14 11:24 · Yahoo
Longeveron (LGVN) Q1 2026 Earnings Transcript
2026-05-13 22:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.